Trial reportThe Journal of allergy and clinical immunology2020
Development and initial validation of the Asthma Severity Scoring System (ASSESS).
Trial report in The Journal of allergy and clinical immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Severe Asthma Research Program
PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study
Who cites it
16 citing papers in PubMed, 29 citations in OpenAlex.
- Digital Communication Technology: Does Offering a Choice of Modality Improve Medication Adherence and Outcomes in a Persistent Asthma Population?The Permanente journal · 2020Trial
- Increased high sensitivity C-reactive protein in more severe wheeze/asthma phenotypes in child- and adulthood in ALLIANCE.Respiratory research · 2026Observational
- COMSA-MEWS: a simple quantitative algorithm for determining response to biologics in severe asthma, tested in a real-world mepolizumab study.ERJ open research · 2026Article
- Preschool Oral Immunotherapy Is Associated With Improved Parental Food Allergy-Specific Anxiety and Quality of Life: A Real-World Observational Study.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2025Observational
- Circulating microRNAs as Potential Diagnostic Tools for Asthma and for Indicating Severe Asthma Risk.International journal of molecular sciences · 2025Article
- Monosensitization vs Polysensitization in Severe Asthma: Implications for Disease Severity.Journal of asthma and allergy · 2025Article
- Asthma Control According to GINA 2023: Does Changing the Criteria Improve Asthma Control?Journal of clinical medicine · 2024Article
- Predictors of persistent poor control and validation of ASSESS score: Longitudinal 5-year follow-up of severe asthma cohort.The journal of allergy and clinical immunology. Global · 2024Article
- Smoking, Urban Housing and Work-Aggravated Asthma are Associated with Asthma Severity in a Cross-Sectional Observational Study.Journal of asthma and allergy · 2024Article
- Treat-to-Target in Atopic Dermatitis.American journal of clinical dermatology · 2024Review
- Cytotoxic CD4Med (New York, N.Y.) · 2023Article
- Definitions of non-response and response to biological therapy for severe asthma: a systematic review.ERJ open research · 2023Review
- Children and caregiver proxy quality of life from peanut oral immunotherapy trials.Clinical and translational allergy · 2022Article
- Responsiveness to Parenteral Corticosteroids and Lung Function Trajectory in Adults with Moderate-to-Severe Asthma.American journal of respiratory and critical care medicine · 2021Article
- Feasibility of Discontinuing Biologics in Severe Asthma: An Algorithmic Approach.Journal of asthma and allergy · 2021Review
- A worldwide charter for all children with asthma.Pediatric pulmonology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 15 institutions in 1 country.
Funding
Abstract
backgroundTools for quantification of asthma severity are limited.
objectiveWe sought to develop a continuous measure of asthma severity, the Asthma Severity Scoring System (ASSESS), for adolescents and adults, incorporating domains of asthma control, lung function, medications, and exacerbations.
methodsBaseline and 36-month longitudinal data from participants in phase 3 of the Severe Asthma Research Program (NCT01606826) were used. Scale properties, responsiveness, and a minimally important difference were determined. External replication was performed in participants enrolled in the Severe Asthma Research Program phase 1/2. The utility of ASSESS for detecting treatment response was explored in participants undergoing corticosteroid responsiveness testing with intramuscular triamcinolone and participants receiving biologics.
resultsASSESS scores ranged from 0 to 20 (8.78 ± 3.9; greater scores reflect worse severity) and differed among 5 phenotypic groups. Measurement properties were acceptable. ASSESS was responsive to changes in quality of life with a minimally important difference of 2, with good specificity for outcomes of asthma improvement and worsening but poor sensitivity. Replication analyses yielded similar results, with a 2-point decrease (improvement) associated with improvements in quality of life. Participants with a 2-point or greater decrease (improvement) in ASSESS scores also had greater improvement in lung function and asthma control after triamcinolone, but these differences were limited to phenotypic clusters 3, 4, and 5. Participants treated with biologics also had a 2-point or greater decrease (improvement) in ASSESS scores overall.
conclusionsThe ASSESS tool is an objective measure that might be useful in epidemiologic and clinical research studies for quantification of treatment response in individual patients and phenotypic groups. However, validation studies are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.